Furmonertinib had been approved by the National Medical Products Administration (NMPA) of China for use in the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations.<\/p>\n
Ingredients:<\/strong><\/p>\n Active: Firmonertinib Mesilate (Furmonertinib Mesylate)<\/span><\/p>\n<\/li>\n Excipients: as per local formulation<\/span><\/p>\n<\/li>\n<\/ul>\n Properties:<\/strong><\/p>\n Oral EGFR TKI targeting EGFR-sensitive mutations (exon 19 del, L858R), resistance T790M, exon 20 insertions, and PACC mutations; able to cross blood\u2013brain barrier.<\/span><\/p>\n<\/li>\n<\/ul>\n Packaging Specification:<\/strong><\/p>\n NEWS \/ UPDATES<\/strong><\/p>\n Furmonertinib may be accessed in India through a named-patient import process<\/strong>\u00a0with a valid doctor\u2019s prescription, and\u00a0Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing<\/strong>\u00a0and delivery of specialty medicines subject to regulatory approvals.<\/p>\n Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations.<\/strong>\u00a0Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.<\/p>\n IPN having representation in<\/strong>\u00a0Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.<\/p>\n Named-patient import facilitator contact details<\/strong> Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.<\/em><\/p>\n Note:<\/strong><\/em> Treatment of locally advanced or metastatic non\u2013small cell lung cancer (NSCLC) with EGFR T790M and other sensitizing mutations.<\/p>\n\n
\n
\n
\n
Is Furmonertinib available in India?<\/h4>\n
How to get Furmonertinib\u00a0 Tablets delivered in India?<\/h4>\n
Who can help source Furmonertinib Tablets in India legally?<\/h4>\n
\nCompany Name:<\/strong>\u00a0Indian Pharma Network (IPN)
\nAddress:<\/strong>\u00a060\/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
\nFor sourcing and import coordination of specialty medicines, contact:<\/strong>
\nMr. Tarun:<\/strong>\u00a0+91 9891 296 838
\nMr. Neeraj:<\/strong>\u00a0+91 9811 747 774
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"\n\n
\n Brand Name:<\/strong><\/td>\n Furmonertinib Tablets<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n Furmonertinib Tablets<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n \u2022 Oral Tablets: 40\u202fmg x 28 tablets\/box<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n <\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n NMPA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n